{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:44:14Z","timestamp":1793609054236,"version":"4.5.0"},"reference-count":53,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Pediatr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Effects of SSRI for symptoms of ASD and comorbid conditions are uncertain. We conducted a systematic review and meta-analyses to determine the efficacy and safety of SSRIs in children with ASD on 8 clinically relevant outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched 7 databases to retrieve RCT of SSRIs versus placebo in children with ASD. Two authors independently extracted data, assessed risk of bias and rated the certainty of evidence using the GRADE method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Seven RCTs with a total of 606 participants were included. The evidence is very uncertain on the effect of SSRIs on restricted repetitive behaviors and anxiety symptoms in children with ASD. There is low certainty of the evidence suggesting that SSRIs result in little to no effect on obsessive-compulsive symptoms and disruptive behaviors, and there is moderate certainty of the evidence that SSRIs likely result in little to no difference in global functioning and a slight increase in adverse events. No studies evaluated depressive symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The number of studies on this population remains limited. The current body of evidence shows no benefit of the use of SSRIs in children with ASD. Risk\/benefit assessment should be carefully considered on an individual basis until further evidence is made available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol registration number:<\/jats:title>\n                    <jats:p>PROSPERO-CRD42020169836<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lay Abstract<\/jats:title>\n                    <jats:p>\n                      <jats:bold>Efficacy of SSRIs in children with ASD<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Do SSRIs Help Children with Autism?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>The scope of this systematic review of the literature was to identify if medications called SSRIs (Selective Serotonin Reuptake Inhibitors) are helpful and safe for children with Autism Spectrum Disorder (ASD). These medicines are sometimes used to treat anxiety, obsessive-compulsive behaviors, or other symptoms.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What Did the Study Look At?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>The researchers carefully examined seven studies that included 606 children with ASD. They compared the effects of SSRIs to a placebo (a pill with no active medicine).<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What Did They Find?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>The researchers found that there is not enough data to confidently judge the effect of SSRI on restricted-repetitive behaviors and anxiety symptoms in children with ASD.<\/jats:p>\n                    <jats:p>Data available shows that SSRIs likely don\u2019t improve obsessive-compulsive symptoms or disruptive behaviors in children with ASD.<\/jats:p>\n                    <jats:p>SSRIs probably don\u2019t make a noticeable difference in overall daily functioning in children with ASD.<\/jats:p>\n                    <jats:p>Children taking SSRIs might experience a small increase in side effects like upset stomach or sleep problems.<\/jats:p>\n                    <jats:p>No studies looked at how SSRIs affect depression in children with ASD.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What Does This Mean for Families?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Right now, there isn\u2019t strong evidence to support using SSRIs for children with ASD. Every child is unique, so if you\u2019re considering this medication, it\u2019s essential to weigh the possible risks and benefits with your doctor.<\/jats:p>\n                    <jats:p>More research is needed to provide better guidance for families and physicians.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795565261442820","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:41:38Z","timestamp":1781066498000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Selective Serotonin Reuptake Inhibitors for Children with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-652X","authenticated-orcid":false,"given":"Elisabetta","family":"Trinari","sequence":"first","affiliation":[{"name":"Department of Pediatrics, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-2892","authenticated-orcid":false,"given":"Noella Juliana","family":"Noronha","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-8593","authenticated-orcid":false,"given":"Davide","family":"Papola","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences Section of Psychiatry, University of Verona, Italy"},{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8414-7410","authenticated-orcid":false,"given":"Tahira","family":"Devji","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-6942","authenticated-orcid":false,"given":"Tamara","family":"Navarro","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-7189","authenticated-orcid":false,"given":"Olaf","family":"Kraus de Camargo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"e_1_3_3_2_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"APA","year":"2013","unstructured":"APA. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Journal of Psychiatry; 2013.","edition":"5"},{"key":"e_1_3_3_3_2","unstructured":"World Health Organization. (2019). ICD-11. Mortality and morbidity statistics. https:\/\/icd.who.int\/browse11\/l-m\/en#\/http:\/\/id.who.int\/icd\/entity\/437815624 (accessed March 16 2021)."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12499"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4144"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006696"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8781725"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01142-w"},{"key":"e_1_3_3_9_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"APA","year":"1994","unstructured":"APA. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association; 1994.","edition":"4"},{"key":"e_1_3_3_10_2","volume-title":"ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision","author":"World Health Organization","year":"2004","unstructured":"World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision. 2nd ed. World Health Organization; 2004.","edition":"2"},{"issue":"6","key":"e_1_3_3_11_2","first-page":"1","article-title":"Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2014","volume":"67","author":"Baio J","year":"2018","unstructured":"Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2014. Morb Mortal Wkly Rep Surveill Summ. 2018;67(6):1-23.","journal-title":"Morb Mortal Wkly Rep Surveill Summ"},{"key":"e_1_3_3_12_2","unstructured":"Centers for Disease Control and Prevention (CDC). (2024). Data & statistics on autism spectrum disorder. https:\/\/www.cdc.gov\/ncbddd\/autism\/data.html (accessed March 16 2021)."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61539-1"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30289-5"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v15.i5.103575"},{"issue":"5","key":"e_1_3_3_16_2","article-title":"Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD)","volume":"5","author":"Reichow B","year":"2018","unstructured":"Reichow B, Hume K, Barton EE, Boyd BA. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2018;5(5):CD009260.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1362361315577218"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-017-3153-x"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-2851K"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-006-0147-5"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-016-2879-1"},{"issue":"11","key":"e_1_3_3_22_2","article-title":"Methylphenidate for children and adolescents with autism spectrum disorder","volume":"11","author":"Sturman N","year":"2017","unstructured":"Sturman N, Deckx L, van Driel ML. Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database Syst Rev. 2017;11(11):CD011144.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2015.08.013"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15010055"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e318179964f"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-019-04291-8"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.1329"},{"issue":"8","key":"e_1_3_3_28_2","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)","volume":"2013","author":"Williams K","year":"2013","unstructured":"Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2013;2013(8):CD004677.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14685"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-019-04120-y"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00810"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-2477-9"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2020.03.007"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/08039488.2022.2075460"},{"issue":"5","key":"e_1_3_3_35_2","article-title":"New generation antidepressants for depression in children and adolescents: a network meta-analysis","volume":"5","author":"Hetrick SE","year":"2021","unstructured":"Hetrick SE, McKenzie JE, Bailey AP, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev. 2021;5(5):CD013674.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch4"},{"issue":"1","key":"e_1_3_3_38_2","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"Wong SS","year":"2006","unstructured":"Wong SS, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc. 2006;94(1):41-47.","journal-title":"J Med Libr Assoc"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.09.016"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-017-3282-2"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0000000000000334"},{"key":"e_1_3_3_42_2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"e_1_3_3_43_2","unstructured":"McMaster University. PROMID (Patient-reported Outcome Measures Minimal Important Difference database). Available at: https:\/\/promid.mcmaster.ca\/ (accessed March 16 2021)."},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.11.024"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000220854.79144.e7"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2020-300164"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"e_1_3_3_49_2","first-page":"375","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.0","author":"Sch\u00fcnemann HJ","unstructured":"Sch\u00fcnemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz NG. Chapter 14: completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0. Cochrane, London. pp.375-402. Available at: https:\/\/training.cochrane.org\/handbook (accessed March 16, 2021)."},{"key":"e_1_3_3_50_2","first-page":"403","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.0","author":"Sch\u00fcnemann HJ","unstructured":"Sch\u00fcnemann HJ, Vist GE, Higgins JPT, et al. Chapter 15: interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0. Cochrane, London. pp.403-431. Available at: https:\/\/training.cochrane.org\/handbook (accessed March 16, 2021)."},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300627"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.30"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-005-3305-2"},{"issue":"7818","key":"e_1_3_3_54_2","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne JA","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343(7818):d4002.","journal-title":"BMJ"}],"container-title":["Clinical Medicine Insights: Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795565261442820","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795565261442820","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795565261442820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:41:55Z","timestamp":1781066515000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795565261442820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"alternative-id":["10.1177\/11795565261442820"],"URL":"https:\/\/doi.org\/10.1177\/11795565261442820","relation":{},"ISSN":["1179-5565","1179-5565"],"issn-type":[{"value":"1179-5565","type":"print"},{"value":"1179-5565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"11795565261442820"}}